Neurocognitive Disorders Associated with PCSK9 Inhibitors: a Pharmacovigilance Disproportionality Analysis
Amandine Gouverneur, Paola Sanchez-Peña, G. Veyrac, Joe‐Elie Salem, Bernard Bégaud, Julien Bezin
Topics & Concepts
MedicinePharmacovigilanceNeurocognitivePCSK9EvolocumabAdverse Event Reporting SystemAdverse effectAlirocumabPostmarketing surveillancePharmacologyPsychiatryInternal medicineCognitionApolipoprotein A1CholesterolLDL receptorApolipoprotein BLipoproteinPharmacovigilance and Adverse Drug ReactionsLipoproteins and Cardiovascular HealthHealthcare Systems and Challenges